Dubensky Thomas W. 4
4 · Tempest Therapeutics, Inc. · Filed Jan 6, 2022
Insider Transaction Report
Form 4
Dubensky Thomas W.
DirectorPresident
Transactions
- Award
Stock Option (Right to Buy)
2022-01-04+53,100→ 53,100 totalExercise: $5.45Exp: 2032-01-03→ Common Stock (53,100 underlying)
Footnotes (1)
- [F1]These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service.